

Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application

## May 20-21, 2004

Washington Marriott 1221 22<sup>nd</sup> Street, NW Washington, DC 20037

## **Cosponsored by:**

Division of Cancer Control and Population Sciences, NCI Division of Cancer Epidemiology and Genetics, NCI Office of Women's Health, NCI

## **Goals and Objectives:**

- Identify cancer risk prediction model applications and their usefulness in planning intervention trials; estimating the population burden of disease; creating benefit/risk indices and clinical decision making processes; and designing prevention strategies
- Discuss the strengths and limitations of cancer risk prediction models in current use and under development
- Discuss methodological issues relevant to the evaluation, validation, and discrimination of cancer risk prediction models
- Identify ways to improve current and future cancer risk prediction models, incorporating new clinical, environmental, and genetic data
- Identify research needs and population data resources for future cancer risk prediction modeling and validation; disseminate this information to the scientific community

# Thursday, May 20, 2004

8:00 a.m.	Registration and Continental Breakfast
8:30 a.m.	<b>Introduction and Perspectives: Cancer Control and Population Sciences</b> <i>Robert Croyle—Director, Division of Cancer Control and Population Sciences,</i> <i>National Cancer Institute</i>
	<b>Introduction and Perspectives: Cancer Epidemiology and Genetics</b> <i>Robert Hoover—Director, Epidemiology and Biostatistics Program, Division of</i> <i>Cancer Epidemiology and Genetics, National Cancer Institute</i>
8:45 a.m.	<b>Workshop Overview and Objectives</b> Andrew Freedman
9:00 a.m.	<b>Session I: Applications of Cancer Risk Prediction Models</b> <i>Moderator: Andrew Freedman</i>
	Clinical Use of Risk Prediction Models Speaker: Laura Esserman
	Estimating Population Burden of Disease Speaker: Karen Kuntz
	Application of Cancer Risk Prediction Models: Intervention Trials Speaker: Joe Costantino
10:00 a.m.	<b>Session II: Cancer Risk and Susceptibility Gene Prediction Models in Use and Development</b> (Oral Presentation followed by Poster Session)
	A Breast Cancer Prediction Model Incorporating Familial and Personal Risk Factors Speaker: Jack Cuzick
	Poster Session Rooms: Thomas Room and Salon C
11:00 a.m.	<b>Session III: Goals and Issues in the Development of Cancer Risk Prediction</b> <b>Models for Various Purposes</b> <i>Moderator: Graham Colditz</i>
	Panelists: Mitchell Gail, Bernard Rosner, Beverly Rockhill, Colin Begg

#### **Topics to be discussed:**

Developing Risk Models

- to incorporate clinical, epidemiologic, and/or biological/genetic markers (e.g., melanoma vs. Gail Model)
- for rare vs. common cancers (e.g., ovary vs. breast)
- using different design methodologies and data sources (e.g., cohorts vs. case-control vs. expert opinion)
- using specialized vs. generalized populations
- for clinical decision making
- for individual vs. population-wide prevention strategies

#### 12:30 p.m. Working Lunch

Lessons Learned From Cardiovascular Risk Models: Experience from the Framingham Study Speaker: Lisa Sullivan

1:15 p.m. Session IV: Risk Assessment Models for Predicting Cancer Susceptibility Genes and Cancer Risk Moderator: Daniela Seminara

The BOADICEA model of genetic susceptibility to breast and ovarian cancer: updating, validation and predictions *Speaker: Antonis Antoniou* 

Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers: Study Design and Analysis Issues Speaker: Tim Rebbeck

Susceptibility Prediction in Familial Colon Cancer Speaker: Giovanni Parmigiani

Risk Assessment for HNPCC *Speaker: Chris Amos* 

Genetic Susceptibility Risk Models in Clinical Decision Making Speaker: Susan Domchek

#### 3:30 p.m. Break

### 3:45 p.m. Session V: Preliminary Discussion of Key Objectives and Research Gaps (To be finalized on Friday, with report by panel members) *Moderator: Patricia Hartge*

Identify research issues, gaps, priorities, and resources needed to advance the field of cancer risk prediction. Make specific recommendations for implementation.

Breakout Discussion Sessions:

#### • Session 1: Salons A&B

Risk prediction models for clinical decision making, intervention studies, and population-based prevention strategies (focus on breast) *Breakout leaders: Joe Costantino, Jack Cuzick, Laura Esserman, and Victor Vogel* 

#### • Session 2: Room 3017

Risk prediction models for clinical decision making, intervention studies, and population-based prevention strategies (focus on lung, colorectal, melanoma, and cancers other than breast) *Breakout leaders: Peter Bach, Graham Colditz, Ernie Hawk, and Tom Imperiale* 

#### • Session 3: Logan Room

Risk prediction models for genetic susceptibility Breakout leaders: David Euhus, Judy Garber, and Tim Rebbeck

### • Session 4: Room 3016

Risk prediction model evaluation and validation Breakout leaders: Michael Kattan, Dan McGee, Martin Schumacher, and Ewout Steyerberg

- 5:30 p.m. Poster Session Revisited (*Light Refreshments*)
- 6:30 p.m. Dinner on your own at nearby restaurants (in small groups)

# Friday, May 21, 2003

7:30 a.m.	Continental Breakfast
8:00 a.m.	<b>Session VI: Validation and Evaluation Methodology</b> <i>Moderator: Susan Hilsenbeck</i>
	General Talk on Criteria for Model Assessment Speaker: <i>Ruth Pfeiffer</i>
	Variability Explained: Calibration, Goodness of Fit, and Unbiased Estimation <i>Speaker: Dan McGee</i>
	Comparing the Accuracy of Prediction Models Speaker: Michael Kattan
	Assessment of Prediction Error of Risk Prediction Models Speaker: Martin Schumacher
9:30 a.m.	Break
9:45 a.m.	Presentation on Current Population Resources for the Development and Validation of Cancer Risk and Susceptibility Prediction Models <i>Speaker: Daniela Seminara</i>
10:00 a.m.	<b>Session VII: Discussion, Summary and Future Research Directions and Wrap-Up</b> (This will finalize the discussion on the previous day.) <i>Moderator: Rachel Ballard-Barbash</i>
	• <b>Report from Breakout Session 1:</b> Risk prediction models for clinical decision making, intervention studies, and population-based prevention strategies (focus on breast)
	• <b>Report from Breakout Session 2:</b> Risk prediction models for clinical decision making, intervention studies, and population-based prevention strategies (focus on lung, colorectal, melanoma, and cancers other than breast)
	• <b>Report from Breakout Session 3:</b> Risk prediction models for genetic susceptibility
	• <b>Report from Breakout Session 4:</b> Risk prediction model evaluation and validation
Noon	Adjourn